Literature DB >> 31010409

Factors Associated With Receipt of Cognitive-Behavioral Therapy or Prolonged Exposure Therapy Among Individuals With PTSD.

Carissa van den Berk Clark1, Rachel Moore1, Scott Secrest1, Peter Tuerk1, Sonya Norman1, Ursula Myers1, Patrick J Lustman1, F David Schneider1, Jacqueline Barnes1, Randy Gallamore1, Muhammad Ovais1, James Alex Plurad1, Jeffrey F Scherrer1.   

Abstract

OBJECTIVE: The aim of this study was to systematically review variables associated with initiation of trauma-centered cognitive-behavioral therapy (TC-CBT) among individuals with posttraumatic stress disorder (PTSD).
METHODS: PubMed, PsycINFO, Web of Science, Published International Literature on Traumatic Stress (PILOTS), and Scopus were searched in a systematic manner up to 2018, and 26 relevant studies were recovered and analyzed.
RESULTS: The average weighted initiation rate was 6% in larger hospital systems with a high rate of trauma and 28% in outpatient mental health settings (range 4%-83%). Older age (odds ratio [OR]=1.56, 95% confidence interval [CI]=0.51-1.61), female gender (OR=1.18, 95% CI=1.08-1.27), black or other racial-ethnic minority group (OR=1.16, 95% CI=1.03-1.28), Veterans Affairs PTSD service connection status (OR=2.30, 95% CI=2.18-2.42), mental health referral (OR=2.28, 95% CI=1.05-3.50), greater staff exposure to TC-CBT (OR=2.30, 95% CI=2.09-2.52), adaptability of TC-CBT to staff workflow (OR=4.66, 95% CI=1.60-7.72), greater PTSD severity (OR=1.46, 95% CI=1.13-1.78), and comorbid depression (OR=1.21, 95% CI=1.14-1.29) increased the likelihood of TC-CBT initiation, whereas delayed treatment reduced the likelihood of TC-CBT initiation (OR=0.93, 95% CI=0.92-0.95). Qualitative studies showed that mental health beliefs (stigma and lack of readiness), provider organizational factors (low availability, privacy issues), and patient lack of time (logistics) were perceived as barriers to initiation by patients and providers.
CONCLUSIONS: TC-CBT initiation increased among patients who were older and female. Initiation was also higher among providers who had more exposure to TC-CBT in their work environment and when TC-CBT fit into their existing workflow.

Entities:  

Keywords:  Cognitive behavioral therapy; Posttraumatic stress disorder (PTSD; Prolonged Exposure Therapy; Treatment Initiation; behavioral health services utilization

Mesh:

Year:  2019        PMID: 31010409      PMCID: PMC6702958          DOI: 10.1176/appi.ps.201800408

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  46 in total

1.  Predictors of Initiation and Engagement of Cognitive Processing Therapy Among Veterans With PTSD Enrolled in Collaborative Care.

Authors:  Kathleen M Grubbs; John C Fortney; Jeffrey M Pyne; Teresa Hudson; William Mark Moore; Paul Custer; Ronald Schneider; Paula P Schnurr
Journal:  J Trauma Stress       Date:  2015-12

Review 2.  Who seeks treatment after a traumatic event and who does not? A review of findings on mental health service utilization.

Authors:  Jelena Jankovic Gavrilovic; Matthias Schützwohl; Mina Fazel; Stefan Priebe
Journal:  J Trauma Stress       Date:  2005-12

3.  Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan.

Authors:  Charles W Hoge; Jennifer L Auchterlonie; Charles S Milliken
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

4.  Measuring use of evidence based psychotherapy for posttraumatic stress disorder.

Authors:  Brian Shiner; Leonard W D'Avolio; Thien M Nguyen; Maha H Zayed; Yinong Young-Xu; Rani A Desai; Paula P Schnurr; Louis D Fiore; Bradley V Watts
Journal:  Adm Policy Ment Health       Date:  2013-07

5.  Acceptability of prolonged exposure therapy among U.S. Iraq war veterans with PTSD symptomology.

Authors:  Shannon M Kehle-Forbes; Melissa A Polusny; Christopher R Erbes; Heather Gerould
Journal:  J Trauma Stress       Date:  2014-08

Review 6.  Cognitive-behavioral therapy for sleep disturbances in treating posttraumatic stress disorder symptoms: A meta-analysis of randomized controlled trials.

Authors:  Fiona Yan-Yee Ho; Christian S Chan; Kristen Nga-Sze Tang
Journal:  Clin Psychol Rev       Date:  2015-09-25

7.  Help-seeking behaviours of individuals with mood disorders.

Authors:  JianLi Wang; Scott B Patten; Jeanne V A Williams; Shawn Currie; Cynthia A Beck; Colleen J Maxwell; Nady El-Guebaly
Journal:  Can J Psychiatry       Date:  2005-09       Impact factor: 4.356

8.  Increased utilization of prolonged exposure and cognitive processing therapy over time: A case example from a large Veterans Affairs posttraumatic stress disorder clinic.

Authors:  Natalie E Hundt; Juliette M Harik; Karin E Thompson; Terri L Barrera; Shannon Reynolds Miles
Journal:  Psychol Serv       Date:  2017-03-13

9.  Treatment of posttraumatic stress disorder in U.S. combat veterans: a meta-analytic review.

Authors:  Jason Goodson; Amy Helstrom; Jacqueline M Halpern; Michael P Ferenschak; Seth J Gillihan; Mark B Powers
Journal:  Psychol Rep       Date:  2011-10

10.  What would you choose? Sertraline or prolonged exposure in community and PTSD treatment seeking women.

Authors:  Norah C Feeny; Lori A Zoellner; Matig R Mavissakalian; Peter P Roy-Byrne
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

View more
  2 in total

Review 1.  How does PTSD treatment affect cardiovascular, diabetes and metabolic disease risk factors and outcomes? A systematic review.

Authors:  Carissa van den Berk Clark; Vruta Kansara; Margarita Fedorova; Tiffany Ju; Tess Renirie; Jaewon Lee; Jesse Kao; Emmanuel T Opada; Jeffrey F Scherrer
Journal:  J Psychosom Res       Date:  2022-03-23       Impact factor: 4.620

2.  Challenges in recruiting and retaining adolescents with abuse-related posttraumatic stress disorder: lessons learned from a randomized controlled trial.

Authors:  Anna Vogel; Hannah Comtesse; Rita Rosner
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2020-04-16       Impact factor: 3.033

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.